| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/25/2002 | CN1091443C New imidazoline compounds, process for preparing them and pharmaceutical composition containing them |
| 09/25/2002 | CN1091441C Amlo dipine mesylate and its preparation and application |
| 09/25/2002 | CN1091381C Medicine composition for curing angiocardiopathy and cerebrovascular disease and its preparation method |
| 09/25/2002 | CN1091368C Pharmaceutical composition comprising coenzyme Q10 |
| 09/24/2002 | US6455734 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 09/24/2002 | US6455674 Polypeptide for use in the diagnosis and treatment of tissue oxygenation defects |
| 09/24/2002 | US6455584 Growth inhibition of vascular smooth muscle; prevention or therapy of the restenosis after ptca. |
| 09/24/2002 | US6455582 Treating cancer |
| 09/24/2002 | US6455578 Aromatic derivatives and iron complexes thereof for the use as normalizing agents of the iron level |
| 09/24/2002 | US6455574 Administering a combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof for treatment of combined hypertension and hyperlipidemia |
| 09/24/2002 | US6455572 Estrogen agonist/antagonist metabolites |
| 09/24/2002 | US6455564 Oral administration of (5r)-(methylamino)-5,6-dihydro-4h-imidazo(4,5,1-ij)quinolin-2( '1h)-one or -thione |
| 09/24/2002 | US6455562 Cyclic AMP-specific phosphodiesterase inhibitors |
| 09/24/2002 | US6455561 Administering benzofuran derivative for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase iv or tumour necrosis factor |
| 09/24/2002 | US6455542 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress |
| 09/24/2002 | US6455538 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ols |
| 09/24/2002 | US6455532 Pyrazinone thrombin inhibitors |
| 09/24/2002 | US6455529 Adhesion receptor antagonists |
| 09/24/2002 | US6455525 Heterocyclic substituted pyrazolones |
| 09/24/2002 | US6455522 Cyclic sulfonamide derivatives as metalloproteinase inhibitors |
| 09/24/2002 | US6455520 Benzamide derivatives and their use as cytokine inhibitors |
| 09/24/2002 | US6455510 Chemical Compounds |
| 09/24/2002 | US6455502 Compounds and compositions as protease inhibitors |
| 09/24/2002 | US6455291 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/24/2002 | US6455283 Amino acid sequence of polypeptide; for recombinant cell culture production of this growth factor; anticarcinogenic agents; wound healing agents |
| 09/24/2002 | US6455269 Method for localized administration of fibrinolytic metalloproteinases |
| 09/24/2002 | CA2261426C Benzimidazole cyclooxygenase-2-inhibitors |
| 09/20/2002 | WO2001070704A1 Novel imidazole derivatives with anti-inflammatory activity |
| 09/20/2002 | CA2403732A1 Novel imidazole derivatives with anti-inflammatory activity |
| 09/20/2002 | CA2377453A1 Method of preventing retinopathy of prematurity in a neonate |
| 09/19/2002 | WO2002073213A2 Assay |
| 09/19/2002 | WO2002073208A2 Anti-epileptogenic agents |
| 09/19/2002 | WO2002072888A2 Polymorphisms in the human cmoat gene and uses thereof |
| 09/19/2002 | WO2002072827A1 Traf3-binding b cell-specific receptor |
| 09/19/2002 | WO2002072826A2 Neurotrophic factors |
| 09/19/2002 | WO2002072794A2 Immunoglobulin superfamily proteins |
| 09/19/2002 | WO2002072780A2 Igf antagonist peptides |
| 09/19/2002 | WO2002072778A2 Method for identifying inhibitors of g protein coupled receptor signaling |
| 09/19/2002 | WO2002072636A2 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 09/19/2002 | WO2002072616A2 Transfection complexes |
| 09/19/2002 | WO2002072608A2 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS |
| 09/19/2002 | WO2002072602A2 Somatostatin antagonists |
| 09/19/2002 | WO2002072599A1 Anti-apoptosis agents or regeneration promoters comprising ginsenosides |
| 09/19/2002 | WO2002072598A1 Steroids as agonists for fxr |
| 09/19/2002 | WO2002072585A2 Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| 09/19/2002 | WO2002072584A2 Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders |
| 09/19/2002 | WO2002072579A1 Triazolopyridines as anti-inflammatory agents |
| 09/19/2002 | WO2002072577A2 Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors. |
| 09/19/2002 | WO2002072573A1 Imidazolidine derivatives, their preparation, and their use as antinflamatory agent. |
| 09/19/2002 | WO2002072570A2 Non-imidazole compounds as histamine h3 antagonists |
| 09/19/2002 | WO2002072569A1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same |
| 09/19/2002 | WO2002072558A1 Anti-thrombotic carboxylic acid amides, the production thereof and use of the same as medicaments |
| 09/19/2002 | WO2002072548A2 Heterocyclic compounds and their use as histamine h4 ligands. |
| 09/19/2002 | WO2002072543A2 Rxr activating molecules |
| 09/19/2002 | WO2002072539A1 Diphenyl derivatives |
| 09/19/2002 | WO2002072536A1 Urea derivatives having vanilloid receptor (vr1) antagonist activity |
| 09/19/2002 | WO2002072528A1 Fluorinated trienes and their use as rxr modulators |
| 09/19/2002 | WO2002072202A1 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| 09/19/2002 | WO2002072147A1 Medicinal compositions containing bile acid transporter inhibitor |
| 09/19/2002 | WO2002072127A2 Modulation of smooth muscle cell proliferation by vegf-x or antagonists thereof |
| 09/19/2002 | WO2002072120A1 Compositions comprising matrine and dictamnine for treating or preventing cancer and other diseases |
| 09/19/2002 | WO2002072119A1 Salvia hispanica l. (chia) in the management and treatment of cardiovascular disease, diabetes and associated risk factors |
| 09/19/2002 | WO2002072118A1 Process for obtention of decoctions of vitis labrusca and vitis vinifera skins |
| 09/19/2002 | WO2002072112A1 Use of selenite or preparations containing selenite for treating wounds |
| 09/19/2002 | WO2002072104A2 Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
| 09/19/2002 | WO2002072103A1 Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
| 09/19/2002 | WO2002072100A2 Pharmaceutical composition containing pde v inhibitors and surfactants |
| 09/19/2002 | WO2002072099A1 Therapeutic and/or preventive agent for diabetic ischemic heart disease |
| 09/19/2002 | WO2002072097A1 Remedies and/or preventives for diabetic ischemic heart diseases |
| 09/19/2002 | WO2002072083A1 Novel inhibitors of formation of advanced glycation endproducts (ages) |
| 09/19/2002 | WO2002072074A1 Method to prepare microparticles metoprolol that contain |
| 09/19/2002 | WO2002072034A2 Chronotherapeutic dosage forms |
| 09/19/2002 | WO2002072033A2 Chronotherapeutic dosage forms containing glucocorticosteroid |
| 09/19/2002 | WO2002072030A2 High affinity integrin polypeptides and uses thereof |
| 09/19/2002 | WO2002071874A2 Composition improving age-related physiological deficits and increasing longevity |
| 09/19/2002 | WO2002071827A2 Retinoid x receptor modulators |
| 09/19/2002 | WO2002055663A3 Srebp pathway modulation through targeting hisrs |
| 09/19/2002 | WO2002050070A3 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
| 09/19/2002 | WO2002050028A3 Substituted benzoindoles as spla2 inhibitors |
| 09/19/2002 | WO2002033079A3 Human g-protein coupled receptor and uses thereof |
| 09/19/2002 | WO2002030876A3 Cyclic carboxylic acids as integrin antagonists |
| 09/19/2002 | WO2002018553A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/19/2002 | WO2002018341A3 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 09/19/2002 | WO2002014355A3 Novel mitogen activated kinase |
| 09/19/2002 | WO2002014311A3 Urea compounds and methods of uses |
| 09/19/2002 | WO2002010192A3 Somatostatin analogues |
| 09/19/2002 | WO2002002765A3 Chimeric promoters for controlling expression in smooth muscle cells |
| 09/19/2002 | WO2001085956A3 Lipid metabolism enzymes |
| 09/19/2002 | WO2001083729A3 Vectors for ocular transduction and use thereof for genetic therapy |
| 09/19/2002 | WO2001083514A3 Nucleic acids encoding a regulator of a g protein signaling, rgs18, and uses thereof |
| 09/19/2002 | WO2001072702A3 Amidino compounds useful as nitric oxide synthase inhibitors |
| 09/19/2002 | US20020133023 Antitumor agents, osteoporosis |
| 09/19/2002 | US20020133018 Calcium channel blockers; cardiovascular disorders; side effect reduction |
| 09/19/2002 | US20020133017 Chromatographic separation of enantiomers of lactones |
| 09/19/2002 | US20020133008 Sexual disorder therapy; cardiovascular disorders; antidiabetic agents; gastrointestinal disorders |
| 09/19/2002 | US20020132979 Monoclonal antibody for use in the diagnosis, prevention and treatment of tumors |
| 09/19/2002 | US20020132978 VEGF-modulated genes and methods employing them |
| 09/19/2002 | US20020132852 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use |
| 09/19/2002 | US20020132849 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 09/19/2002 | US20020132845 Compositions and methods for the prevention and treatment of tissue ischemia |